146 related articles for article (PubMed ID: 17504383)
21. Clinical implications and prognostic value of single and combined biomarkers in endometrial carcinoma.
Li M; Zhao L; Shen D; Li X; Wang J; Wei L
Chin Med J (Engl); 2014; 127(8):1459-63. PubMed ID: 24762589
[TBL] [Abstract][Full Text] [Related]
22. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
Alvarez T; Miller E; Duska L; Oliva E
Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
[TBL] [Abstract][Full Text] [Related]
23. Value of circulating tumor cells positive for thyroid transcription factor-1 (TTF-1) to predict recurrence and survival rates for endometrial carcinoma.
Zhang Y; Qu X; Qu PP
J BUON; 2016; 21(6):1491-1495. PubMed ID: 28039713
[TBL] [Abstract][Full Text] [Related]
24. [Correlations of p-AKT with PTEN, P53, HER-2 expressions in endometrial carcinoma and their relationship with patient survival].
Zhang XM; Liang Y; Dong Y; Zhang Y; Wang Y; Meng YT; Li T
Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Feb; 44(1):135-41. PubMed ID: 22353917
[TBL] [Abstract][Full Text] [Related]
25. PTEN mutations do not cause nuclear beta-catenin accumulation in endometrial carcinomas.
Wappenschmidt B; Wardelmann E; Gehrig A; Schöndorf T; Maass N; Bonatz G; Gassel AM; Pietsch T; Mallmann P; Weber BH; Schmutzler RK
Hum Pathol; 2004 Oct; 35(10):1260-5. PubMed ID: 15492994
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of p53, bcl-2 and EGFR in carcinoma of the endometrium.
Athanassiadou P; Petrakakou E; Liossi A; Nakopoulou L; Zerva C; Dimopoulos A; Athanassiades P
Acta Cytol; 1999; 43(6):1039-44. PubMed ID: 10578976
[TBL] [Abstract][Full Text] [Related]
27. [Relationships between the molecular biomarkers and the clinicopathologic features and prognosis in endometrial carcinoma].
Yao YY; Xu WZ; Wang Y; Shen DH; Wang JL; Wei LH
Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Oct; 43(5):743-8. PubMed ID: 22008688
[TBL] [Abstract][Full Text] [Related]
28. Equivalent Survival of p53 Mutated Endometrial Endometrioid Carcinoma Grade 3 and Endometrial Serous Carcinoma.
Brett MA; Atenafu EG; Singh N; Ghatage P; Clarke BA; Nelson GS; Bernardini MQ; Köbel M
Int J Gynecol Pathol; 2021 Mar; 40(2):116-123. PubMed ID: 32265358
[TBL] [Abstract][Full Text] [Related]
29. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.
Huvila J; Talve L; Carpén O; Edqvist PH; Pontén F; Grénman S; Auranen A
Gynecol Oncol; 2013 Sep; 130(3):463-9. PubMed ID: 23777659
[TBL] [Abstract][Full Text] [Related]
30. [Significance of phosphoinositide 3 kinase/AKT pathway alterations in endometrial carcinoma].
Yang X; Dong Y; Zhang XM; Liang Y; Zhang Y; Meng YT; Wang Y; Wang W; Nong L; Li T; Liao QP
Zhonghua Bing Li Xue Za Zhi; 2011 Dec; 40(12):799-804. PubMed ID: 22336203
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathologic Association and Prognostic Value of Microcystic, Elongated, and Fragmented (MELF) Pattern in Endometrial Endometrioid Carcinoma.
Kihara A; Yoshida H; Watanabe R; Takahashi K; Kato T; Ino Y; Kitagawa M; Hiraoka N
Am J Surg Pathol; 2017 Jul; 41(7):896-905. PubMed ID: 28418994
[TBL] [Abstract][Full Text] [Related]
32. The prognostic value of molecular biomarkers in tissue removed by curettage from FIGO stage 1 and 2 endometrioid type endometrial cancer.
Steinbakk A; Skaland I; Gudlaugsson E; Janssen EA; Kjellevold KH; Klos J; Løvslett K; Fiane B; Baak JP
Am J Obstet Gynecol; 2009 Jan; 200(1):78.e1-8. PubMed ID: 18976730
[TBL] [Abstract][Full Text] [Related]
33. CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence.
Kurnit KC; Kim GN; Fellman BM; Urbauer DL; Mills GB; Zhang W; Broaddus RR
Mod Pathol; 2017 Jul; 30(7):1032-1041. PubMed ID: 28281553
[TBL] [Abstract][Full Text] [Related]
34. High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma.
Garcia-Dios DA; Lambrechts D; Coenegrachts L; Vandenput I; Capoen A; Webb PM; Ferguson K; ; Akslen LA; Claes B; Vergote I; Moerman P; Van Robays J; Marcickiewicz J; Salvesen HB; Spurdle AB; Amant F
Gynecol Oncol; 2013 Feb; 128(2):327-34. PubMed ID: 23219661
[TBL] [Abstract][Full Text] [Related]
35. Overexpression of Wnt7a is associated with tumor progression and unfavorable prognosis in endometrial cancer.
Liu Y; Meng F; Xu Y; Yang S; Xiao M; Chen X; Lou G
Int J Gynecol Cancer; 2013 Feb; 23(2):304-11. PubMed ID: 23321718
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical expression of PTEN and beta-catenin for endometrial intraepithelial neoplasia in Japanese women.
Norimatsu Y; Moriya T; Kobayashi TK; Sakurai T; Shimizu K; Tsukayama C; Ohno E
Ann Diagn Pathol; 2007 Apr; 11(2):103-8. PubMed ID: 17349568
[TBL] [Abstract][Full Text] [Related]
37. PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus.
Kimura F; Watanabe J; Hata H; Fujisawa T; Kamata Y; Nishimura Y; Jobo T; Kuramoto H
J Cancer Res Clin Oncol; 2004 Mar; 130(3):161-8. PubMed ID: 14689303
[TBL] [Abstract][Full Text] [Related]
38. PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients.
Westin SN; Ju Z; Broaddus RR; Krakstad C; Li J; Pal N; Lu KH; Coleman RL; Hennessy BT; Klempner SJ; Werner HM; Salvesen HB; Cantley LC; Mills GB; Myers AP
Mol Oncol; 2015 Oct; 9(8):1694-703. PubMed ID: 26045339
[TBL] [Abstract][Full Text] [Related]
39. Expression of phosphatase and tensin homologue in imprint smears of endometrial carcinoma.
Kosmas K; Mitropoulou G; Provatas I; Stamoulas M; Marouga A
Cytopathology; 2018 Dec; 29(6):558-564. PubMed ID: 30007089
[TBL] [Abstract][Full Text] [Related]
40. Expression of PTEN in endometrial liquid-based cytology.
Di Lorito A; Zappacosta R; Capanna S; Gatta DM; Rosini S; Schmitt FC
Acta Cytol; 2014; 58(5):495-500. PubMed ID: 25358681
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
